Literature DB >> 17160688

Subacute cardiotoxicity caused by anthracycline therapy in children: can dexrazoxane prevent this effect?

Gábor T Kovács1, Hajna Erlaky, Kornélia Tóth, Erzsébet Horváth, Judit Szabolcs, Monika Csóka, László Jókúti, Dániel Erdélyi, Judit Müller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17160688     DOI： 10.1007/s00431-006-0370-2

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  6 in total

1.  Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.

Authors:  Lubomir Elbl; Hana Hrstkova; Iva Tomaskova; Bohumir Blazek; Jaroslav Michalek
Journal:  Eur J Pediatr       Date:  2005-07-26       Impact factor: 3.183

Review 2.  Exposure to anthracyclines during childhood causes cardiac injury.

Authors:  Steven E Lipshultz
Journal:  Semin Oncol       Date:  2006-06       Impact factor: 4.929

3.  Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

Authors:  L C Kremer; E C van Dalen; M Offringa; J Ottenkamp; P A Voûte
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

Review 4.  Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.

Authors:  Karlijn A Wouters; Leontien C M Kremer; Tracie L Miller; Eugene H Herman; Steven E Lipshultz
Journal:  Br J Haematol       Date:  2005-12       Impact factor: 6.998

Review 5.  Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.

Authors:  Risto S Cvetković; Lesley J Scott
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 6.  Epidemiology of anthracycline cardiotoxicity in children and adults.

Authors:  M A Grenier; S E Lipshultz
Journal:  Semin Oncol       Date:  1998-08       Impact factor: 4.929
  6 in total
  4 in total

Review 1.  Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.

Authors:  V Ashutosh Rao
Journal:  Antioxid Redox Signal       Date:  2012-10-26       Impact factor: 8.401

2.  Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.

Authors:  Hyoung Soo Choi; Eun Sil Park; Hyoung Jin Kang; Hee Young Shin; Chung Il Noh; Yong Soo Yun; Hyo Seop Ahn; Jung Yun Choi
Journal:  J Korean Med Sci       Date:  2010-08-12       Impact factor: 2.153

3.  Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathy.

Authors:  Giuseppe Distefano
Journal:  Ital J Pediatr       Date:  2009-11-20       Impact factor: 2.638

4.  Evaluation of the cost-effectiveness of dexrazoxane for the prevention of anthracycline-related cardiotoxicity in children with sarcoma and haematologic malignancies: a European perspective.

Authors:  Sarah Dewilde; Kevin Carroll; Emilia Nivelle; James Sawyer
Journal:  Cost Eff Resour Alloc       Date:  2020-02-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.